Accro Bioscience
PrivateLast Round
Series C
May 18, 2026
Total Funding Raised
$112M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Accro Bioscience operates in Healthcare & Life Sciences and is based in Suzhou, New York. Its latest recorded funding round was a Series C round in May 2026.
Accro Bioscience is a biotechnology company that pioneers the discovery, development, and commercialization of novel therapeutics for inflammatory and autoimmune diseases by targeting molecular mechanisms of regulatory cell death.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Accro Bioscience Comparables
Compare Accro Bioscience with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| 成都赜灵生物医药科技有限公司 | 86% | |
| 杭州高光制药股份有限公司 | 86% | |
| Odyssey Therapeutics | 84% |
For institutional investors. Book with your work email.
Accro Bioscience Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | May 18, 2026 | ||||
| Series B Extension | Mar 14, 2025 | ||||
| Series B | Jan 4, 2022 | ||||
| Series A | Sep 1, 2017 |
For institutional investors. Book with your work email.
Accro Bioscience Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| TCG Crossover | Series C |
| Oriza Holdings | Series C, Series B |
| Morningside Ventures | Series B Extension, Series A |
| OrbiMed | Series C |
| 中南创投基金 | Series B |
| TCG Crossover | Series C |
| Cenova Capital | Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 78% MoM.
- May 18, 2026
$50M round led by OrbiMed
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventAug 13, 2026
Accropeutics Inc. plans to present efficacy and safety results from a Phase 1b study of AC-101 for moderate-to-severe ulcerative colitis at UEG Week 2026 in Spain on Oct 17th–20th '26.
For institutional investors. Book with your work email.
Accro Bioscience Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Accro Bioscience's valuation, stock price, and market status.
Is Accro Bioscience a public or private company?
Accro Bioscience is a private company.
What is the current stock price of Accro Bioscience?
Accro Bioscience is a private company, so its shares have no public market price. Caplight tracks Accro Bioscience's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Accro Bioscience worth (valuation)?
Valuation information for Accro Bioscience is not publicly available.
Can I buy Accro Bioscience stock?
Accro Bioscience shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Accro Bioscience's last funding round?
Accro Bioscience's most recent funding round was Series C on May 18, 2026.
Who are the main investors in Accro Bioscience?
Key investors in Accro Bioscience include Morningside Ventures, OrbiMed, Hongtai Aplus, Shenzhen Capital Group.
Will Accro Bioscience IPO soon?
No public IPO plans have been announced for Accro Bioscience.
How can I track Accro Bioscience secondary market activity?
Caplight tracks bids, offers, and trades in Accro Bioscience's shares on secondary markets.